OBJECTIVES: @entity5202 ( @entity5202 ) is a chronic inflammatory condition that causes esophageal remodeling and @entity850 formation. We compared the clinical course of symptoms, endoscopic findings, histology, and changes in phenotype over time in @entity5202 @entity1 with inflammatory and fibrostenotic phenotypes. METHODS: Data were obtained from @entity5202 @entity1 from three medical centers and followed prospectively. Endoscopic features and histology from index and follow-up endoscopies were recorded. Behavior was classified as inflammatory if endoscopic findings demonstrated furrows or white plaques and as fibrostenotic if endoscopic findings included fixed @entity850 . RESULTS: Two hundred and fifty-six @entity5202 @entity1 were included in the analysis. The mean age was 32  18 years, 25% of @entity1 were <18 years, 89% of @entity1 were Caucasians, and 74% of @entity1 were male. The mean duration of symptoms before diagnosis was 6.8  7.2 years with a follow-up of 1.7  1.9 years (maximum follow-up of 12 years). Fifty-four percent of @entity1 presented with fibrostenotic @entity5202 , whereas 46% presented with inflammatory @entity5202 . @entity1 with @entity32 were younger than those with @entity66 (24  19 vs. 39  15 years, P<0.001). @entity1 with @entity66 had a longer duration of symptoms than those with @entity32 (8.1  7.7 vs. 5.3  6.3 years, P=0.002). Over the study period, 47 (18%) had remission of inflammatory @entity5202 , 68 (27%) continued to have @entity32 , 74 (29%) continued to have @entity66 , 65 (25%) fibrostenotic @entity1 had regression of @entity82 , and 2 @entity1 (1%) progressed from @entity32 to @entity66 . @entity1 who had regression from their fibrostenosis were more likely than @entity1 who continued to demonstrate fibrostenosis to have a decrease in proximal (54% vs. 32%, P<0.001) and distal (70% vs. 38%, P<0.001) @entity1712 . CONCLUSIONS: Most @entity5202 @entity1 maintained their phenotype or had an improvement with <1% progressing from inflammatory to fibrostenosis. This suggests that early therapeutic strategies aimed at controlling @entity32 may interrupt, decrease, or prevent the remodeling @entity82 in @entity5202 .

Early Comparison of Inflammatory vs. Fibrostenotic Phenotype in XXXX in a Multicenter Longitudinal Study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'inflammatory disease'] @entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophilia'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity5202 :: ('MESH:D057765', 'Disease') :: ['Eosinophilic esophagitis', 'EoE'] @entity66 :: ('MESH:D004194', 'Disease') :: ['fibrostenotic disease'] @entity850 :: ('MESH:D003251', 'Disease') :: ['stricture', 'rings or strictures']
@entity5202 :: (MESH:D057765,Disease) :: ['Eosinophilic Esophagitis']
